Search
Triplizumab
go.drugbank.com/drugs/DB30669Investigationaltriplizumab is a biologic drug. triplizumab is under investigation in clinical trial NCT06486220 (PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized
Human Menstrual Blood-derived Stem Cells
go.drugbank.com/drugs/DB15738InvestigationalStem cells are self-renewing and proliferate without differentiation, with the two major groups being embryonic stem cells (ESCs) and adult stem cells (ASC). Differentiation occurs under different conditions into different cell types. ES...
ALTU-135
go.drugbank.com/drugs/DB05330InvestigationalALTU-135, the Company's orally administered enzyme replacement therapy for patients with pancreatic insufficiency, is manufactured by blending three drug substance enzymes: lipase, protease and amylase. This consistent and pure enzyme co...
Lacosamide
go.drugbank.com/drugs/DB06218ApprovedInvestigational[A262681] Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008.
Gabapentin
go.drugbank.com/drugs/DB00996ApprovedInvestigationalGabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment o...
Darvadstrocel
go.drugbank.com/drugs/DB16581ApprovedInvestigationalWithdrawn[L39759] It is the first mesenchymal stem cell therapy approved in Europe for this therapeutic indication. … [A244524] Darvadstrocel was first approved by the European Commission on March 23, 2018, under the brand name Alofisel.
AV608
go.drugbank.com/drugs/DB05072InvestigationalAV608 is a NK-1 antagonist. It is developed for the treatment of Social anxiety disorder (SAD), irritable bowel syndrome (IBS) and overactive bladder (OAB).
Selpercatinib
go.drugbank.com/drugs/DB15685ApprovedInvestigational[L13604] Selpercatinib is also approved by the European Commission.
Anifrolumab
go.drugbank.com/drugs/DB11976ApprovedInvestigationalAnifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus. The standard therapy for systemic lupus ery...
Povidone
go.drugbank.com/drugs/DB11061ApprovedInvestigationalWithdrawnsomewhat controversial, as it was demonstrated in a few clinical studies that the application of the compound in wounds was associated with impaired wound healing, reduced wound strength, or infection in open
Mixtures: Best Choice Artificial Tears, Best Choice Eye Drops Advanced Relief